Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvespimycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 16/20 | 0.84 |
| ▸ | HSP90AB1 known ✓ | P08238 | 4/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvespimycin SCHEMBL13403878 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449725 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL16226150 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL14418059 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL13040902 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449728 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL16226152 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL13928049 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL21250611 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 | |
| Alvespimycin SCHEMBL5449716 | 1.00 | ERBB2 (0.89) | ERBB2HSP90AA1HSP90AB1ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5175 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| US-20260060991-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CLONAL HEMATOPOIESIS | THE JACKSON LABORATORY (US) | 2026-03-05 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025137459-A1 | METHODS OF TREATING PAIN USING SENOLYTICS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4569087-A2 | METHODS AND COMPOSITIONS FOR INHIBITING CLONAL HEMATOPOIESIS | The Jackson Laboratory (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250151714-A1 | Methods for Improving Tissue Graft Storage Conditions through the Reduction of Senescence | RESTORATION BIOLOGICS LLC | 2025-05-15 | — | — | US | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| WO-2007096393-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | claimed |
| WO-2007077261-A1 | NEW METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT | TOPOTARGET SWITZERLAND SA (CH) | 2007-07-12 | — | — | WO | claimed |
| EP-1794137-A2 | SPECIFIC KINASE INHIBITORS | Kosan Biosciences, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | claimed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | claimed |
| US-20060115457-A1 | Biocompatible hydrogel compositions | HNOJEWYJ OLEXANDER | 2006-06-01 | — | — | US | claimed |
| CN-1767792-A | Devices, methods and compositions for preventing restenosis | KOSAN BIOSCIENCES INC (US) | 2006-05-03 | — | — | CN | claimed |
| US-20060079494-A1 | Specific kinase inhibitors | KOSAN BIOSCIENCES INCORPORATED | 2006-04-13 | — | — | US | claimed |
| WO-2006036941-A2 | SPECIFIC KINASE INHIBITORS | KOSAN BIOSCIENCES INCORPORATED (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2006034467-A2 | BIOCOMPATIBLE HYDROGEL COMPOSITIONS | JULIAZ INC. (US) | 2006-03-30 | — | — | WO | claimed |